Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands allow for labeling with
18F and radiometals for endoradiotherapy. rhPSMA-7.3 has been designated as a lead …

As the use of radioligand therapy moves earlier in the prostate cancer timeline, minimizing
the absorbed dose to normal organs while maintaining high tumor radiation doses becomes …

Prostate-specific membrane antigen (PSMA)–targeted radioligand therapy is increasingly
used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed …

The objective of this study was to determine the safety, kinetics, and dosimetry of the 177Lu-
labeled prostate-specific membrane antigen (PSMA) small molecules 177Lu-PSMA I&T and …

Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands are applicable as
radiochemical twins for both diagnostic PET imaging and endoradiotherapy. On the basis of …

The prostate-specific membrane antigen (PSMA)–targeted radiohybrid (rh) ligand [177Lu]
Lu-rhPSMA-7.3 has recently been assessed in a pretherapeutic dosimetry study on prostate …

Methods The patients' age range was 74±7 years at the time of the investigated treatment
cycle, and the mean injected activity was 7416±218 MBq. Planar images at several time …

177Lu-prostate-specific membrane antigen (PSMA)–617 enables targeted delivery of β-
particle radiation to prostate cancer. We determined its radiation dosimetry and relationships …

Rationale: Evaluation of alternative radionuclides for use in prostate-specific membrane
antigen (PSMA)-targeted radioligand therapy (RLT) is currently focusing on 161 Tb, which …

Simple Summary In patients with progressive metastasized castration-resistance prostate
cancer PSMA radioligand therapies have shown promising results regarding clinical safety …